secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0000950170-23-010318
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology reprices executive stock options to $2.21 per share
------------------------------------------------------------------

- Board approved reducing exercise prices of outstanding pre-IPO options from $5.34-$8.71 to $2.21, the closing price on March 24, 2023.
- CEO Lara Sullivan had 1,052,286 options repriced; CFO/COO Pamela Connealy 332,569; CMO Jay Feingold 174,774.
- Repricing applies only to options granted under the 2019 Plan to current employees; all other terms unchanged.
- Board cites improved retention and motivation without additional equity dilution or cash compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023010318/0000950170-23-010318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023010318/pyxs-20230328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer